AMELIORATION OF THE DELETERIOUS EFFECTS OF DONOR BRAIN DEATH
改善供体脑死亡的有害影响
基本信息
- 批准号:8457430
- 负责人:
- 金额:$ 5.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-06 至 2015-08-05
- 项目状态:已结题
- 来源:
- 关键词:AcuteAntibodiesBiopsyBrain DeathChronicClinicalDataData AnalysesEducational CurriculumFacultyFamily suidaeGene ExpressionGraft ToleranceHarvestImmunologyImmunosuppressionImmunosuppressive AgentsImplantIncidenceInflammationInflammatoryInstructionInterleukin-1Interleukin-6LaboratoriesLife ExpectancyLungLung TransplantationLung diseasesMalignant NeoplasmsMeasuresMiniature SwineModelingNational Research Service AwardsOpportunistic InfectionsPathway interactionsPatientsPharmaceutical PreparationsPre-Clinical ModelResearchResearch PersonnelResearch TrainingResuscitationScientistSerumStagingT-Cell ActivationTechniquesTimeToxic effectTrainingTraining ProgramsTransplant RecipientsTransplantationWorkclinical practicecytokinedesignex vivo perfusionimmune activationimplantationinflammatory markerlung allograftpreclinical studypreventpublic health relevancesuccess
项目摘要
DESCRIPTION (provided by applicant): The success of lung transplantation in patients with end-stage lung disease has been limited by a high incidence of chronic rejection, which has only been partially ameliorated by the use of immunosuppressive drugs. However, in many preclinical studies, we have observed that the induction of transplant tolerance prevents acute and chronic rejection, and eliminates the need for long-term immunosuppression, which in patients often leads to opportunistic infection, toxicity, and malignancy. Our center has demonstrated the ability to induce tolerance in swine receiving fully mismatched lung allografts, when transplanted under ideal laboratory conditions (healthy anesthetized donors with minimal ischemic times). However, when the same lungs are procured from a brain-dead lung donor (which is the common clinical scenario), tolerance is abrogated. We hypothesize that the inflammatory state associated with donor brain death prevents the induction of tolerance in this preclinical model. Our long-term objective is to develop strategies to minimize the negative impact of pro-inflammatory states on the donor graft. In this proposal, we will determine whether 1) the blockade of specific inflammatory pathways or 2) ex vivo treatment of the donor graft prior to implantation will restore tolerogenicity to grafts procured from a brain-dead donor.
Specifically, we will use antibodies to block the inflammatory cytokines IL-6 and IL1, and perfuse the donor graft ex vivo with a stabilizing perfusate. Our results will uncover potential strategies
to maximize tolerance induction that will be clinically applicable to patients undergoing lung transplantation for end- stage lung disease. The research training program at our center is ideally suited to developing young investigators into independent scientists. This is accomplished through a comprehensive training curriculum including supervised experimental work, didactic instruction, and technical training. Fellows at our center participate in all aspect of research, including experimental planning and design and data analysis and interpretation. Our fellows also have ample opportunities to present to and interact with many world-class faculties in the field of transplant immunology.
描述(由申请人提供):肺移植在终末期肺病患者中的成功受到慢性排斥反应高发生率的限制,使用免疫抑制药物只能部分改善。然而,在许多临床前研究中,我们观察到移植耐受的诱导可以预防急性和慢性排斥反应,并消除对长期免疫抑制的需要,长期免疫抑制在患者中通常会导致机会性感染,毒性和恶性肿瘤。 我们的中心已经证明了在理想的实验室条件下(健康的麻醉供体,缺血时间最短),在接受完全不匹配的肺同种异体移植物的猪中诱导耐受的能力。然而,当同样的肺从脑死亡的肺供体获得时(这是常见的临床情况),耐受性被废除。我们假设与供体脑死亡相关的炎症状态阻止了该临床前模型中耐受的诱导。我们的长期目标是制定策略,以尽量减少促炎状态对供体移植物的负面影响。 在本提案中,我们将确定1)特异性炎症通路的阻断或2)植入前供体移植物的离体处理是否会恢复从脑死亡供体获得的移植物的耐受性。
具体来说,我们将使用抗体来阻断炎性细胞因子IL-6和IL-1,并用稳定的灌注液离体灌注供体移植物。我们的研究结果将揭示潜在的战略
以最大限度地诱导耐受,这将在临床上适用于接受肺移植治疗终末期肺病的患者。 我们中心的研究培训计划非常适合将年轻的研究人员培养成独立的科学家。这是通过一个全面的培训课程,包括监督实验工作,教学指导和技术培训。我们中心的研究员参与研究的各个方面,包括实验规划和设计以及数据分析和解释。我们的研究员也有充分的机会提出,并与移植免疫学领域的许多世界一流的院系互动。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maria Lucia Madariaga其他文献
Maria Lucia Madariaga的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maria Lucia Madariaga', 18)}}的其他基金
Applying User-centered Design and Implementation Science to Enhance Prehabilitation for Frail Older Adults Undergoing Lung Cancer Surgery
应用以用户为中心的设计和实施科学来加强接受肺癌手术的体弱老年人的康复
- 批准号:
10727197 - 财政年份:2023
- 资助金额:
$ 5.57万 - 项目类别:
AMELIORATION OF THE DELETERIOUS EFFECTS OF DONOR BRAIN DEATH
改善供体脑死亡的有害影响
- 批准号:
8724980 - 财政年份:2013
- 资助金额:
$ 5.57万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 5.57万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 5.57万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 5.57万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 5.57万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 5.57万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 5.57万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 5.57万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 5.57万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 5.57万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 5.57万 - 项目类别: